• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Vedolizumab
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    Entyvio
    Takeda
    RX
    partial basket chart
    Entyvio

    Selective Immunosuppressants. Vedolizumab 300 mg.
    VIAL (pwdr. for conc. for sol. for infus.): 1. Ulcerative colitis: 300 mg admin. by IV infus. at zero, two and six wks. and then every 8 wks. thereafter. Ther. for pts. with ulcer. colit. should be discont. if no evidence of therapeutic benefit is observed by wk 10.
    Pts. who exper. decr. in response may incr. in dosing freq. to 300 mg every 4 wks.
    Pts. who have respond. to tmt. with 300 mg, corticost. may be reduced and/or discount. in accord. with standard of care. 2. Crohn’s disease: 300 mg admin. by IV infus. at zero, two and six wks. and then every 8 wks. thereafter.
    Pts. with Crohn’s dis., who have not shown a response may benefit from a dose at wk 10. Ther. should be cont. every 8 wks. from wk 14 in respond. pts. Therapy for pts. with Crohn’s dis. should be discont. if no eviden. of therap. benefit is observ. by wk 14. See lit.
    Tmt. of adult pts. with moder.-sever. act. ulcer. colitis who have had an inadeq. response with, lost response to, or were intolerant to either convent. ther. or a TNFα antagonist.
    Tmt. of adult pts. with moder.-sever. act Crohn’s dis. who have had an inadeq. response with, lost response to, or were intolerant to either convent. ther. or a ther. or a TNFα antagonist.
    C/I: Hypersens. Act. severe infec. such as tuberculosis, sepsis, CMV, listeriosis, and opportunis. infec. such as PML.

    CLOSE